Erlotinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Pancreatic Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Tarceva: unresectable recurrent or advanced NSCLC after chemotherapy
Product first approved 2007pharmatimes.com
EU
  • Tarceva: advanced or metastatic NSCLC (EGFR-mutation and maintenance), and metastatic pancreatic cancer with gemcitabine
Product first approved 2005EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (59)
Non-Small Cell Lung Cancer
NCT02193282 · National Cancer Institute (NCI)
2015-02-11 – 2027-02-03 · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02795884 · Yonsei University
2016-06 – 2020-11 · NSCLC
What this study did
NCT02775006 · The Netherlands Cancer Institute
2016-10-14 – 2019-04 · Carcinoma, Non-small Cell Lung
What this study did
NCT02140333 · The First Affiliated Hospital of Guangzhou Medical University
2013-08 – 2018-12 · NSCLC, EGFR Mutation
What this study did
NCT01667562 · Hoffmann-La Roche
Run by former owner Roche
2012-01-20 – 2017-09-07 · Non-Small Cell Lung Cancer
What this study did
NCT02134015 · Daiichi Sankyo
2014-03 – 2016-11-11 · Lung Cancer, Non-small Cell Lung Cancer
What this study did
NCT01887795 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2013-08 – 2016-08 · Multiple Brain Metastases, Non-small-cell Lung Cancer
What this study did
NCT01351415 · Hoffmann-La Roche
Run by former owner Roche
2011-06-25 – 2016-06-25 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT02031744 · Hoffmann-La Roche
Run by former owner Roche
2014-01-22 – 2016-01-06 · Non-Small Cell Lung Cancer
What this study did
NCT01328951 · Hoffmann-La Roche
Run by former owner Roche
2011-09 – 2016-01 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT01652469 · ETOP IBCSG Partners Foundation
2012-08 – 2015-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02178397 · Centre Francois Baclesse
2014-06 – 2015-09 · NSCLC Patients With EGFR Activating Mutation
What this study did
NCT02001896 · Xinjiang Medical University
2013-12 – 2015-06 · Non-Small Cell Lung Cancer
What this study did
NCT01024413 · Chinese Society of Lung Cancer
2009-07 – 2015-06 · Thoracic Neoplasms
What this study did
NCT00738881 · National Cancer Institute (NCI)
2008-10 – 2014-12 · Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT00883779 · Hoffmann-La Roche
Run by former owner Roche
2009-04 – 2014-12 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT00257608 · Genentech, Inc.
2006-01 – 2014-11 · Non-Small Cell Lung Cancer
What this study did
NCT01342965 · Hoffmann-La Roche
Run by former owner Roche
2011-03 – 2014-04 · Non-Small Cell Lung Cancer
What this study did
NCT00153803 · Dartmouth-Hitchcock Medical Center
2005-05 – 2014-04 · Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC
What this study did
NCT01183858 · Hoffmann-La Roche
Run by former owner Roche
2010-10 – 2014-02 · Non-Small Cell Lung Cancer
What this study did
NCT00955695 · National Cancer Center, Korea
started 2009-05 · Lung Cancer
What this study did
NCT00637910 · Fatebenefratelli and Ophthalmic Hospital
2007-11 – 2013-02 · Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT00457392 · Pfizer
2007-07 – 2012-12 · Carcinoma, Non-Small Cell Lung
What this study did
NCT00718315 · Hoffmann-La Roche
Run by former owner Roche
2009-04 – 2012-06 · Non-Small Cell Lung Cancer
What this study did
NCT00556322 · Hoffmann-La Roche
Run by former owner Roche
2006-03 – 2012-06 · Non-Small Cell Lung Cancer
What this study did
NCT00349219 · National Cancer Institute, Naples
2006-12 – 2012-06 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT00096265 · National Cancer Institute (NCI)
2004-10-06 – 2012-04-01 · Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT00673049 · Pfizer
2008-05 – 2012-04 · Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous Cell
What this study did
NCT00300586 · Hospices Civils de Lyon
2006-06 – 2011-03 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT00556712 · Hoffmann-La Roche
Run by former owner Roche
2006-01 – 2010-11 · Non-Small Cell Lung Cancer
What this study did
NCT00440414 · Hellenic Oncology Research Group
2006-04 – 2010-04 · Non Small Cell Lung Cancer
What this study did
NCT00275132 · University College, London
2005-04 – 2009-04 · Lung Cancer
What this study did
NCT00268684 · Tel-Aviv Sourasky Medical Center
started 2005-05 · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
What this study did
NCT00091663 · Genentech, Inc.
2004-08 – 2005-08 · Lung Cancer, Non-small-cell Lung Carcinoma
What this study did
NCT00036647 · OSI Pharmaceuticals
2001-11-01 – 2004-01-30 · Carcinoma, Non-small-cell Lung
What this study did
Pancreatic Cancer
NCT01013649 · National Cancer Institute (NCI)
2010-04-05 – 2025-09-04 · Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
What this study did
NCT00634725 · GERCOR - Multidisciplinary Oncology Cooperative Group
2008-02 – 2014-09 · Pancreatic Cancer
What this study did
NCT00440167 · PD Dr. med. Volker Heinemann
2006-06 – 2012-12 · Pancreatic Cancer
What this study did
NCT02694536 · Hoffmann-La Roche
Run by former owner Roche
2006-08-01 – 2009-11-19 · Pancreatic Cancer
What this study did
NCT00026338 · NCIC Clinical Trials Group
2001-10-29 – 2009-02-10 · Pancreatic Cancer
What this study did
NCT00040183 · OSI Pharmaceuticals
2001-11-29 – 2004-01-15 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT02488330 · Hoffmann-La Roche
Run by former owner Roche
2015-08-27 – 2018-06-29 · Solid Tumor
What this study did
NCT00402779 · M.D. Anderson Cancer Center
2006-11-03 – 2018-06-04 · Oral Cancer
What this study did
NCT00901901 · Bayer
2009-05-21 – 2018-05-23 · Carcinoma, Hepatocellular
What this study did
NCT00442455 · Grupo de Investigación Clínica en Oncología Radioterapia
2006-01 – 2015-08 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00686114 · Wenzhou Medical University
2008-05 – 2014-12 · Esophageal Cancer
What this study did
Phase 2/3 (3)
Non-Small Cell Lung Cancer
NCT01407822 · Guangdong Association of Clinical Trials
2011-12-05 – 2022-12 · Non-small Cell Lung Cancer
What this study did
NCT03074864 · Guangdong Provincial People's Hospital
2017-02-27 – 2020-06-30 · Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor
What this study did
Other / comorbidity
NCT00448240 · Henry Ford Health System
2007-02 – 2012-01 · Head and Neck Cancer, Carcinoma, Squamous Cell
What this study did
Phase 2 (352)
Non-Small Cell Lung Cancer
NCT00977470 · Massachusetts General Hospital
2009-10 – 2027-12 · Non-small Cell Lung Cancer
What this study did
NCT01708954 · National Cancer Institute (NCI)
2013-02-13 – 2027-03-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02098954 · Hunan Province Tumor Hospital
2014-07-01 – 2025-12-12 · Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT01306045 · National Cancer Institute (NCI)
2011-02-08 – 2024-07-17 · Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
What this study did
NCT03126799 · National Cancer Center, Korea
2016-11-01 – 2023-07-20 · EGFR Positive Non-small Cell Lung Cancer
What this study did
NCT01470716 · National Cancer Center, Korea
2012-01 – 2022-06-30 · NSCLC Stage II, NSCLC, Stage IIIA
What this study did
NCT01248247 · M.D. Anderson Cancer Center
2011-06-02 – 2020-11-30 · Lung Cancer
What this study did
NCT01683175 · Tianjin Medical University Cancer Institute and Hospital
2012-08 – 2020-10 · Non-small Cell Lung Cancer Stage III
What this study did
NCT00871923 · M.D. Anderson Cancer Center
2009-03-26 – 2019-12-04 · Non-small Cell Lung Cancer, Brain Cancer
What this study did
NCT02655536 · National Taiwan University Hospital
2017-08-01 – 2019-12 · Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
What this study did
NCT03123484 · China Medical University, China
2017-04 – 2019-10 · Non Small Cell Lung Cancer
What this study did
NCT00137839 · Pasi A. Janne, MD, PhD
2004-11 – 2019-07 · Adenocarcinoma, Non-small Cell Lung Cancer
What this study did
NCT02770014 · Dana-Farber Cancer Institute
2016-06 – 2019-06-19 · Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer
What this study did
NCT00835471 · Dutch Society of Physicians for Pulmonology and Tuberculosis
2009-03 – 2019-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02556593 · Sun Yat-sen University
2015-09 – 2019-04 · Non-Small Cell Lung Carcinoma
What this study did
NCT01573702 · UNC Lineberger Comprehensive Cancer Center
2012-12-11 – 2019-03-15 · Non Small Cell Lung Cancer
What this study did
NCT01518621 · Oslo University Hospital
2012-05 – 2018-12-10 · Cancer
What this study did
NCT01562028 · ETOP IBCSG Partners Foundation
2012-06 – 2018-10-31 · Lung Cancer
What this study did
NCT01714908 · Jinming Yu
2012-12-14 – 2018-10-20 · Non-small Cell Lung Cancer
What this study did
NCT01822496 · National Cancer Institute (NCI)
2013-11-04 – 2018-06-04 · Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT00563784 · M.D. Anderson Cancer Center
2007-11 – 2018-05-30 · Non-Small Cell Lung Cancer, Lung Cancer
What this study did
NCT01866410 · National Cancer Institute (NCI)
2013-05-20 – 2018-03-30 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT00411632 · M.D. Anderson Cancer Center
2006-11-29 – 2018-02-23 · Lung Cancer
What this study did
NCT01487265 · SCRI Development Innovations, LLC
2014-03 – 2017-12-11 · Non Small Cell Lung Cancer
What this study did
NCT02037997 · Fudan University
2013-12 – 2017-12 · Non Small Cell Lung Cancer
What this study did
NCT02738983 · Hangzhou Cancer Hospital
2012-01 – 2017-12 · Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)
What this study did
NCT01965275 · Anhui Medical University
2013-10 – 2017-12 · Self Efficacy, Drug Toxicity
What this study did
NCT00567359 · Massachusetts General Hospital
2007-12 – 2017-12 · Non-small Cell Lung Cancer
What this study did
NCT00126581 · National Cancer Institute (NCI)
2005-08-15 – 2017-11-28 · Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT00950365 · Albert Einstein College of Medicine
2006-04 – 2017-11-17 · Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT01260181 · Hoffmann-La Roche
Run by former owner Roche
2011-03-31 – 2017-09-29 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT01857271 · Albert Einstein College of Medicine
2013-11 – 2017-08-31 · Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
What this study did
NCT00547105 · University of Texas Southwestern Medical Center
2007-06-25 – 2017-07-06 · Lung Cancer
What this study did
NCT01410214 · Chinese Lung Cancer Surgical Group
2011-05 – 2017-07 · Non-small Cell Lung Cancer Stage IIIA
What this study did
NCT02064491 · Finnish Lung Cancer Group
2014-02 – 2017-05-31 · Non-small Cell Lung Cancer
What this study did
NCT01378962 · Hoffmann-La Roche
Run by former owner Roche
2011-03-31 – 2017-01-31 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT02095782 · Guangdong Association of Clinical Trials
2014-03 – 2017-01-20 · Non-small-cell Lung Cancer
What this study did
NCT01104155 · Eisai Inc.
2010-02-22 – 2017-01-18 · Non-small Cell Lung Cancer
What this study did
NCT00997334 · David M. Jackman, MD
2010-02 – 2017-01 · Non-small Cell Lung Cancer
What this study did
NCT01310036 · Hoffmann-La Roche
Run by former owner Roche
2011-04-30 – 2016-12-30 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT01174563 · Hoffmann-La Roche
Run by former owner Roche
2011-05-23 – 2016-12-20 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT02034097 · GlaxoSmithKline
2014-04 – 2016-12 · Cancer
What this study did
NCT02006043 · Li Zhang
2013-12 – 2016-12 · Non-small Cell Lung Cancer
What this study did
NCT00973310 · Tianjin Medical University Cancer Institute and Hospital
2009-10 – 2016-12 · Carcinoma, Non-Small Cell Lung
What this study did
NCT00661193 · SWOG Cancer Research Network
2008-12 – 2016-12 · Lung Cancer
What this study did
NCT01217619 · Baohui Han
2011-03-02 – 2016-10-30 · Non Small Cell Lung Cancer
What this study did
NCT01395758 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2011-07 – 2016-08 · Metastatic Non-Small Cell Lung Cancer
What this study did
Phase 1/2 (69)
Non-Small Cell Lung Cancer
NCT02039674 · Merck Sharp & Dohme LLC
2014-02-21 – 2021-10-18 · Non-small Cell Lung Carcinoma
What this study did
NCT02535338 · National Cancer Institute (NCI)
2016-04-11 – 2021-09-08 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02424617 · BerGenBio ASA
2015-04-19 – 2021-08-25 · Non-Small Cell Lung Cancer
What this study did
NCT03076164 · Memorial Sloan Kettering Cancer Center
2017-03-01 – 2020-12-18 · Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV, Recurrent Lung Adenocarcinoma, Recurrent Lung Cancer
What this study did
NCT04165031 · Eli Lilly and Company
2019-11-28 – 2020-10-30 · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT01471964 · Fox Chase Cancer Center
2011-10-20 – 2018-04-10 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
What this study did
NCT01801111 · Hoffmann-La Roche
Run by former owner Roche
2013-06-20 – 2017-10-27 · Non-Small-Cell Lung Carcinoma
What this study did
NCT02155465 · Memorial Sloan Kettering Cancer Center
2014-06 – 2017-10 · Lung Cancer
What this study did
NCT01233687 · Ahmad Tarhini
2011-08 – 2014-11 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01259089 · Northwestern University
2011-04-27 – 2014-09-29 · Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
What this study did
NCT00826449 · M.D. Anderson Cancer Center
2009-02 – 2014-06 · Lung Cancer, Non-Small Cell Lung Cancer
What this study did
NCT00452413 · Eli Lilly and Company
2007-05 – 2013-11 · Non-Small Cell Lung Cancer, Malignant Solid Tumor
What this study did
NCT00408499 · University of California, Davis
2006-08 – 2013-01 · Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00280150 · UNC Lineberger Comprehensive Cancer Center
2006-01 – 2013-01 · Lung Cancer
What this study did
NCT00596648 · Exelixis
2008-02-12 – 2012-08-02 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00390429 · University of California, Davis
2002-07 – 2012-08 · Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00778167 · National Cancer Institute (NCI)
2008-10 – 2012-05 · Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT00503971 · Spanish Lung Cancer Group
2008-05 – 2011-12 · Non-small Cell Lung Cancer
What this study did
NCT00147537 · Pfizer
2005-02 – 2011-08 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01188707 · Herlev Hospital
2010-10-01 – 2011-06-30 · Non Small Cell Lung Cancer
What this study did
NCT00716456 · Memorial Sloan Kettering Cancer Center
2008-07 – 2011-05 · Lung Adenocarcinoma
What this study did
NCT00278148 · Nathan Pennell, MD, PhD
2005-10 – 2011-02 · Lung Cancer
What this study did
NCT00453362 · Genentech, Inc.
2006-12 – 2010-04-23 · Non-Small Cell Lung Cancer
What this study did
NCT00387322 · University of California, Davis
2005-03 – 2009-05 · Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00351039 · H. Lee Moffitt Cancer Center and Research Institute
2006-07 – 2008-09 · Non-Small Cell Lung Cancer
What this study did
NCT00101348 · National Cancer Institute (NCI)
2005-01 – 2008-05 · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Colon Cancer, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary
What this study did
NCT00522938 · Chroma Therapeutics
2007-12 – 2008-04 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00251589 · Merck Sharp & Dohme LLC
2006-01 – 2007-10 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00043823 · M.D. Anderson Cancer Center
2002-08-01 – 2006-05-15 · Lung Cancer
What this study did
NCT00063895 · National Cancer Institute (NCI)
2003-04 – 2005-10 · Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx
What this study did
Pancreatic Cancer
NCT06483555 · UNC Lineberger Comprehensive Cancer Center
2025-02-06 – 2027-08 · Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
What this study did
NCT00769483 · M.D. Anderson Cancer Center
2008-11-13 – 2020-09-01 · Pancreatic Cancer, Pancreatic Adenocarcinoma
What this study did
NCT02737228 · CrystalGenomics, Inc.
2016-03 – 2019-08 · Pancreatic Neoplasms
What this study did
NCT01600807 · Dana-Farber Cancer Institute
— · Pancreatic Cancer, Metastatic
What this study did
NCT00260364 · Royal Marsden NHS Foundation Trust
2005-11 – 2011-08 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT06545695 · Northwestern University
2027-07-01 – 2031-06-30 · Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
What this study did
NCT02273362 · National Cancer Institute (NCI)
2014-11-24 – 2022-03-10 · Cirrhosis, Hepatocellular Carcinoma
What this study did
NCT01455389 · Genprex, Inc.
2014-02 – 2020-09-28 · Lung Cancer
What this study did
NCT02044601 · M.D. Anderson Cancer Center
2014-06 – 2019-06 · Lung Cancer
What this study did
NCT00573989 · Wake Forest University Health Sciences
2008-03 – 2017-03 · Head and Neck Cancer
What this study did
NCT02380625 · Clinical Research Management, Inc.
2015-04 – 2016-03 · Ebola Virus Disease
What this study did
NCT01835938 · University Hospital, Strasbourg, France
2013-05 – 2015-05 · Chronic Hepatitis C Infection, HCV Genotype 1b
What this study did
NCT00124657 · St. Jude Children's Research Hospital
2005-03 – 2014-09 · Brain and Central Nervous System Tumors
What this study did
NCT00834678 · Ohio State University Comprehensive Cancer Center
2009-04 – 2014-09 · Breast Cancer
What this study did
NCT01110876 · M.D. Anderson Cancer Center
2011-06 – 2014-07 · Brain Cancer, Glioblastoma Multiforme
What this study did
NCT00301418 · Northwell Health
2006-03 – 2014-05 · Glioblastoma Multiforme, Anaplastic Astrocytoma
What this study did
NCT00112736 · National Cancer Institute (NCI)
2005-04 – 2014-04 · Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor
What this study did
Phase 1 (154)
Non-Small Cell Lung Cancer
NCT04449874 · Genentech, Inc.
2020-07-29 – 2027-12-31 · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
What this study did
NCT02991651 · Io Therapeutics
2016-12-07 – 2025-05-09 · Lung Cancer, Nonsmall Cell
What this study did
NCT00254384 · M.D. Anderson Cancer Center
2005-10-05 – 2024-05-21 · Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02277457 · University of Michigan Rogel Cancer Center
2015-09 – 2021-06 · Non-Small Cell Lung Cancer
What this study did
NCT01911507 · University of California, Davis
2013-08-27 – 2020-08-26 · Recurrent Non-small Cell Lung Cancer
What this study did
NCT02013219 · Hoffmann-La Roche
Run by former owner Roche
2014-04-03 – 2020-02-05 · Non-Small Cell Lung Cancer
What this study did
NCT03050411 · Peking University Third Hospital
2016-05 – 2019-10 · Nonsmall Cell Lung Cancer
What this study did
NCT01859026 · H. Lee Moffitt Cancer Center and Research Institute
2013-12-30 – 2019-08-22 · Lung Cancer, Non-Small Cell Lung Cancer
What this study did
NCT02080078 · AHS Cancer Control Alberta
2014-09 – 2019-04-30 · Non-small Cell Lung Cancer, Advanced Solid Malignancies
What this study did
NCT01998126 · University of Utah
2013-12-02 – 2018-03-29 · Non-small Cell Lung Cancer
What this study did
NCT02342353 · Washington University School of Medicine
2015-05-18 – 2018-02-06 · Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
What this study did
NCT02206763 · Sierra Oncology LLC - a GSK company
2014-10-16 – 2017-02-16 · EGFR Mutated EGFR TKI Naive Metastatic NSCLC
What this study did
NCT02321293 · Lady Davis Institute
2015-08 – 2016-12 · Lung Cancer
What this study did
NCT01839955 · Neelesh Sharma MD PhD
2013-09 – 2016-10 · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT02134886 · National Cancer Institute (NCI)
2014-07 – 2015-09 · HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT01193881 · National Cancer Institute (NCI)
2010-08 – 2015-08 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT00934076 · University of Alabama at Birmingham
2010-02 – 2015-06 · Carcinoma, Non Small Cell Lung
What this study did
NCT01545947 · Celgene
2012-05-01 – 2014-12-11 · Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
What this study did
NCT01515969 · Heather Wakelee
2012-07 – 2014-12 · Non-small Cell Lung Cancer (NSCLC), Recurrent, Non-small Cell Lung Cancer (NSCLC), Stage IV
What this study did
NCT01302808 · University of Texas Southwestern Medical Center
2009-09 – 2014-12 · Lung Cancer, Metastatic Cancer
What this study did
NCT00975182 · Genentech, Inc.
2009-09 – 2014-09 · Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers
What this study did
NCT00966472 · Ottawa Hospital Research Institute
2009-03 – 2014-09 · Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
What this study did
NCT00975767 · Mirati Therapeutics Inc.
2009-08 – 2014-08 · Advanced Malignancies, Non-small Cell Lung Cancer
What this study did
NCT01602289 · Eli Lilly and Company
2012-06 – 2014-08 · Solid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung
What this study did
NCT01594398 · Syndax Pharmaceuticals
2012-05 – 2014-05 · Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
What this study did
NCT00779389 · University of Pittsburgh
2009-01 – 2014-02 · Head and Neck Cancer, Non Small Cell Lung Cancer
What this study did
NCT00965731 · Pfizer
2010-01 – 2014-01 · Non-Small Cell Lung Cancer
What this study did
NCT00397384 · National Cancer Institute (NCI)
2007-01 – 2013-06 · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
What this study did
NCT00707252 · Louisiana State University Health Sciences Center Shreveport
2008-01 – 2012-11 · Non-Small Cell Lung Cancer
What this study did
NCT01026844 · Massachusetts General Hospital
2007-07 – 2012-11 · Non-small Cell Lung Cancer
What this study did
NCT01251796 · Kyowa Kirin Co., Ltd.
2010-12 – 2012-11 · Advanced/Recurrent Non-small-cell Lung Cancer
What this study did
NCT00702182 · National Cancer Centre, Singapore
2008-04 – 2012-10 · Non-Small Cell Lung Cancer
What this study did
NCT01199068 · Daiichi Sankyo Co., Ltd.
2010-06 – 2011-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00692640 · Sanofi
2008-05 – 2011-11 · Cancer, Non-small Cell Lung Cancer
What this study did
NCT01069757 · Kyowa Kirin Co., Ltd.
2010-02 – 2011-09 · Non-small-cell Lung Cancer
What this study did
NCT00581789 · University of Wisconsin, Madison
2007-08 – 2011-08 · Non Small Cell Lung Cancer
What this study did
NCT01115803 · Eli Lilly and Company
2010-03 – 2011-06 · Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
What this study did
NCT00729742 · Merck Sharp & Dohme LLC
2009-02 – 2011-05 · Carcinoma, Non-small Cell Lung
What this study did
NCT00633529 · EMD Serono
2007-11 – 2011-03 · Non-Small Cell Lung Cancer
What this study did
NCT00777699 · Sanofi
2008-08 – 2011-02 · Cancer, Non-Small Cell Lung Cancer
What this study did
NCT00088959 · National Cancer Institute (NCI)
2003-12 – 2010-11 · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT00708448 · University of Utah
2008-03-28 – 2010-08-12 · Cancer, Non Small Cell Lung Cancer
What this study did
NCT00444015 · H. Lee Moffitt Cancer Center and Research Institute
2007-03 – 2010-08 · Non-Small-Cell Lung Carcinoma
What this study did
NCT00569114 · Tragara Pharmaceuticals, Inc.
2007-10 – 2009-11 · Non-small Cell Lung Cancer
What this study did
NCT00619424 · GlaxoSmithKline
2007-11-15 – 2009-09-04 · Lung Cancer, Non-Small Cell
What this study did
NCT00738335 · University of California, San Francisco
2009-01 – 2009-07 · Lung Cancer, Metastatic Cancer
What this study did
NCT00042835 · National Cancer Institute (NCI)
2002-05 – 2008-12 · Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
What this study did
NCT02507375 · Hoffmann-La Roche
Run by former owner Roche
2006-09 – 2008-12 · Non-Small Cell Lung Cancer
What this study did
Phase 4 (15)
Non-Small Cell Lung Cancer
NCT02399566 · Hunan Province Tumor Hospital
2015-05 – 2019-01 · Lung Adenocarcinoma
What this study did
NCT03460678 · Hikma Pharmaceuticals LLC
2018-02-28 – 2018-11-14 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02031601 · Qilu Hospital of Shandong University
2014-01 – 2017-12 · Non-Small-Cell Lung Cancer
What this study did
NCT01320501 · National Guard Health Affairs
2009-10 – 2016-08 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT01402089 · Markus Joerger
2012-01 – 2015-11 · Non Small-cell Lung Cancer, Renal-cell Cancer, Gastrointestinal Stroma Tumor
What this study did
NCT01609543 · Hoffmann-La Roche
Run by former owner Roche
2012-05 – 2015-01 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT02000531 · Hoffmann-La Roche
Run by former owner Roche
2014-01 – 2014-12 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01287754 · Hoffmann-La Roche
Run by former owner Roche
2011-10 – 2013-11 · Non-Small Cell Lung Cancer
What this study did
NCT01230710 · Hoffmann-La Roche
Run by former owner Roche
2011-03 – 2013-09 · Non-Small Cell Lung Cancer
What this study did
NCT01196078 · Hoffmann-La Roche
Run by former owner Roche
2007-02 – 2010-12 · Non-Small Cell Lung Cancer
What this study did
NCT01066884 · Hoffmann-La Roche
Run by former owner Roche
2009-04 – 2009-11 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT00949910 · Hoffmann-La Roche
Run by former owner Roche
2004-11 – 2009-04 · Non-Small Cell Lung Cancer
What this study did
Pancreatic Cancer
NCT00642733 · Hoffmann-La Roche
Run by former owner Roche
2007-08 – 2009-04 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT01299220 · University of Pittsburgh
2010-11 – 2011-09 · Skin Rash
What this study did
NCT04145570 · Quadras Scientific Solutions
2008-10-23 – 2008-11-09 · Lung Cancer
What this study did
Early phase / not applicable (19)
Non-Small Cell Lung Cancer
NCT02194738 · National Cancer Institute (NCI)
2014-09-26 – 2027-09-21 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT02450591 · Memorial Sloan Kettering Cancer Center
2015-05-14 – 2017-12-11 · Oligometastatic Lung Adenocarcinoma
What this study did
NCT01776684 · Samsung Medical Center
2012-06 – 2015-05 · EGFR Mutation Positive Non-small Cell Lung Cancer
What this study did
NCT01889212 · University of Aarhus
2013-04 – 2015-04 · Lung Cancer
What this study did
NCT01378598 · Dana-Farber Cancer Institute
2010-09 – 2012-02 · Lung Cancer
What this study did
NCT00903292 · National Cheng-Kung University Hospital
2009-03 – 2010-12 · Non-Small Cell Lung Cancer
What this study did
NCT00125372 · Dartmouth-Hitchcock Medical Center
2005-12 – 2010-08 · Carcinoma, Non-small-cell Lung
What this study did
NCT00803842 · Northwestern University
2008-10 – 2009-12 · Non Small Cell Lung Cancer
What this study did
NCT00883480 · Spanish Lung Cancer Group
2005-06 – 2008-11 · Non-small Cell Lung Cancer
What this study did
NCT00305617 · The Cleveland Clinic
2004-01 – 2007-12 · Lung Cancer
What this study did
NCT00085280 · National Cancer Institute (NCI)
2004-09 – 2006-10 · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
Pancreatic Cancer
NCT01683422 · Loma Linda University
2013-01-02 – 2019-02-19 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT02239952 · Amsterdam UMC, location VUmc
2014-11 – 2021-11 · Cancer, High-grade Glioma
What this study did
NCT01636908 · Amsterdam UMC, location VUmc
2011-08 – 2019-12-01 · Cancer, Advanced Solid Tumors
What this study did
NCT01393821 · Mayo Clinic
2012-01-23 – 2018-07-14 · Dermatologic Complications, Malignant Neoplasm, Pain
What this study did
NCT02013089 · Sun Yat-sen University
2013-12 – 2017-12 · Gastrointestinal Cancers
What this study did
NCT02015728 · Seattle Children's Hospital
2013-12 – 2017-12 · Recurrent Childhood Brain Tumor
What this study did
NCT00503841 · Barbara Ann Karmanos Cancer Institute
2007-12 – 2010-05 · Breast Cancer
What this study did
NCT00144976 · Institut Claudius Regaud
2003-10 – 2006-12 · Head and Neck Neoplasms
What this study did
Used as active comparator (26)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (12)
Non-Small Cell Lung Cancer
NCT02152631 · Eli Lilly and Company
2014-10-03 – 2026-12 · Non Small Cell Lung Cancer
What this study did
NCT02411448 · Eli Lilly and Company
2015-05-06 – 2026-12 · Metastatic Non-Small Cell Lung Cancer
What this study did
NCT02296125 · AstraZeneca
2014-12-03 – 2025-11-20 · Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
What this study did
NCT03529084 · Novartis Pharmaceuticals
2018-07-24 – 2024-06-03 · Carcinoma, Non-small Cell Lung
What this study did
NCT00130728 · Genentech, Inc.
2005-06-08 – 2019-12-23 · Non-Small Cell Lung Cancer
What this study did
NCT02886195 · Fujian Cancer Hospital
2016-07 – 2019-07 · EGFR Gene Mutation
What this study did
NCT01523587 · Boehringer Ingelheim
2012-03-05 – 2017-12-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02588261 · Astellas Pharma Global Development, Inc.
2016-02-11 – 2017-12-21 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT00364351 · Genzyme, a Sanofi Company
2006-08 – 2016-11 · Non Small Cell Lung Cancer
What this study did
NCT01360554 · Pfizer
2011-06-16 – 2015-09-14 · Non-Small Cell Lung Cancer
What this study did
NCT01487174 · Kadmon Corporation, LLC
2011-12-14 – 2013-07-25 · Carcinoma, Non-Small-Cell Lung
What this study did
Phase 2/3 (2)
Non-Small Cell Lung Cancer
NCT03653546 · Alpha Biopharma (Jiangsu) Co., Ltd.
2018-10-29 – 2022-07-12 · Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
What this study did
NCT02186301 · Clovis Oncology, Inc.
2014-11 – 2017-06-28 · Non-Small Cell Lung Cancer
What this study did
Phase 2 (9)
Non-Small Cell Lung Cancer
NCT04455594 · The First Affiliated Hospital of Guangzhou Medical University
2020-10 – 2025-10 · Non-Small Cell Lung Cancer Stage IIIA
What this study did
NCT02117024 · Heat Biologics
2014-07 – 2018-04 · Non Small Cell Lung Cancer
What this study did
NCT00743938 · Bristol-Myers Squibb
2009-03 – 2012-06 · Non Small Cell Lung Cancer
What this study did
NCT00654420 · Merck Sharp & Dohme LLC
2008-03-19 – 2012-02-13 · Carcinoma, Non-small-cell Lung
What this study did
NCT00550173 · Eli Lilly and Company
2007-11 – 2012-01 · Non-Small-Cell Lung Cancer
What this study did
NCT00732810 · Merck Sharp & Dohme LLC
2008-07 – 2011-06 · Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT00606502 · Spectrum Pharmaceuticals, Inc
2008-01 – 2010-06-24 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT01556191 · Intergroupe Francophone de Cancerologie Thoracique
2012-05-15 – 2020-06-17 · Stage IV Lung Cancer
What this study did
Phase 1/2 (2)
Non-Small Cell Lung Cancer
NCT02574078 · Bristol-Myers Squibb
2015-11-23 – 2020-04-15 · Non-Small Cell Lung Cancer
What this study did
NCT01728181 · University of Utah
2013-11 – 2016-03 · Non-small Cell Lung Cancer, Stage IV Disease, EGFR Unknown or Wild-type
What this study did
Phase 1 (1)
Non-Small Cell Lung Cancer
NCT00456833 · Novartis Pharmaceuticals
2005-06 – 2011-03 · Non Small Cell Lung Cancer
What this study did
Appears in other studies (38)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (10)
Non-Small Cell Lung Cancer
NCT02633189 · National Cancer Institute, Naples
2016-04 – 2024-07 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT02893332 · Sichuan Provincial People's Hospital
2016-01-15 – 2020-08-30 · Stage IV EGFR Mutated Non-Small Cell Lung Cancer
What this study did
NCT02759614 · Guangdong Association of Clinical Trials
2016-04-01 – 2020-03-30 · NSCLC
What this study did
NCT01377376 · Kyowa Kirin Co., Ltd.
2011-07 – 2015-11 · Non-small-cell Lung Cancer
What this study did
NCT01887886 · Hoffmann-La Roche
Run by former owner Roche
2013-12 – 2015-02 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT01158170 · Zhejiang Cancer Hospital
2010-06 – 2013-12 · Non-small Cell Lung Cancer
What this study did
NCT01244191 · Daiichi Sankyo
2011-01-11 – 2012-12-15 · Non Squamous, Non-small-cell Lung Cancer
What this study did
Other / comorbidity
NCT02882984 · Sichuan Provincial People's Hospital
2015-03 – 2020-12 · Stage IV EGFR Mutated NSCL With Brain Metastases
What this study did
NCT02889692 · Shanghai University of Traditional Chinese Medicine
2013-03 – 2017-06-01 · Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02926638 · SWOG Cancer Research Network
2014-06-16 – 2016-10-12 · MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
What this study did
Phase 2 (20)
Non-Small Cell Lung Cancer
NCT03137771 · NRG Oncology
2017-04-07 – 2028-12 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT01897480 · Eli Lilly and Company
2013-08-28 – 2026-01-08 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03720873 · Fujian Cancer Hospital
2018-10 – 2022-09 · EGFR Gene Mutation
What this study did
NCT01532089 · Academic and Community Cancer Research United
2012-03-16 – 2020-08-18 · EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT02704767 · First Affiliated Hospital of Kunming Medical University
2016-06 – 2019-12 · Lung Cancer
What this study did
NCT00100854 · Translational Oncology Research International
2004-10-28 – 2018-09-05 · Lung Cancer
What this study did
NCT01796288 · Wu Jieping Medical Foundation
2012-10 – 2017-10 · Non Small Cell Lung Cancer, Oligometastatic
What this study did
NCT02318368 · AVEO Pharmaceuticals, Inc.
2014-11 – 2017-01 · Non-small Cell Lung Cancer
What this study did
NCT00499655 · City of Hope Medical Center
2007-11 – 2016-12 · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT01763385 · Wu Jieping Medical Foundation
2012-11 – 2016-05 · Non-small-cell Lung Cancer, Brain Metastases
What this study did
NCT02355431 · Incyte Corporation
2014-12 – 2015-09 · Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
What this study did
NCT01186861 · Astellas Pharma Inc
2011-03-04 – 2015-03-11 · Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
What this study did
NCT01027598 · SCRI Development Innovations, LLC
2010-01 – 2014-06 · Non Small Cell Lung Cancer
What this study did
NCT01101334 · Daiichi Sankyo
2010-03 – 2013-04 · Advanced Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT00265317 · Pfizer
2006-06 – 2012-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00854308 · Genentech, Inc.
2009-04 – 2012-01 · Non-Small Cell Lung Cancer
What this study did
NCT00777309 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2008-09 – 2011-08 · Non Small Cell Lung Cancer
What this study did
Pancreatic Cancer
NCT01210911 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2010-08 – 2014-04 · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
What this study did
NCT00709826 · Tragara Pharmaceuticals, Inc.
2008-08 – 2011-05 · Pancreatic Cancer, Metastatic Pancreatic Cancer
What this study did
Phase 1/2 (4)
Non-Small Cell Lung Cancer
NCT06071013 · China Medical University Hospital
2024-02-23 – 2026-08-27 · Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
What this study did
NCT00994123 · Merrimack Pharmaceuticals
2010-02 – 2015-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01211483 · Daiichi Sankyo
2010-09 – 2013-11-23 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT00602030 · Syndax Pharmaceuticals
2008-01-08 – 2012-02-01 · Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT07271446 · Precision Biotech Taiwan Corp.
2018-09-01 – 2023-12-01 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT03628521 · Shanghai Chest Hospital
2018-07-20 – 2020-12-31 · Lung Cancer, Advanced Stage
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT01190241 · Amsterdam UMC, location VUmc
2010-08 – 2017-12 · Advanced Solid Tumors, Inoperable, Metastasis
What this study did

Competitive landscape

This mechanism is crowded: 41 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Erlotinib: this drugApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
Cetuximab
Approved(overall)
Monoclonal antibodyEGFR
Partial signal(overall)
No reviewed efficacy summary in this indication
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
AsandeutertinibPhase 3Small moleculeEGFRWeak signal
NCT05146219: Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
BefotertinibPhase 3Small moleculeEGFRPartial signal
NCT04206072: Median IRC-assessed PFS: 22.1 months (befotertinib) vs 13.8 months (icotinib); HR 0.49 (95% CI 0.36-0.68), P<0.0001
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
FHND9041Phase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
FurmonertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
IcotinibPhase 3Small moleculeEGFRPartial signal
NCT01719536: Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006
NCT01040780: Progression Free Survival (2-7 months): Icotinib 4.6 months (95% CI 3.5 to 6.3) vs Gefitinib 3.4 months (95% CI 2.3 to 3.8)
LimertinibPhase 3Small moleculeEGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR)Reliable signal
NCT04143607: NCT04143607 (limertinib/ASK120067 vs gefitinib first-line trial), primary endpoint median PFS: limertinib 20.7 months vs gefitinib 9.7 months; HR 0.44
Nogapendekin Alfa Inbakicept (Anktiva)Phase 3Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
PruvonertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
RezivertinibPhase 3Small moleculeEGFRReliable signal
NCT03866499: REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001
NCT03812809: ORR by blinded independent central review 64.6% (95% CI 58.0%-70.8%)
Rilertinib (SH-1028)Phase 3Small moleculeEGFRReliable signal
NCT04239833: Median PFS: 19.3 months (rilertinib/SH-1028) vs 9.8 months (gefitinib), HR 0.46, P<0.0001 -- primary endpoint met.
ZipalertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ZoldonrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
PimurutamabPhase 2/3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
ZorifertinibPhase 2/3Small moleculeEGFRPartial signal
NCT03653546: Median PFS by blinded independent central review: 9.6 months (zorifertinib/AZD3759) vs 6.9 months (control, gefitinib or erlotinib); HR 0.719 (95% CI 0.580-0.893), p=0.0024
AtebimetinibPhase 2Small moleculeMEK (MAP2K1/2)not yet gradedNo reviewed efficacy summary in this indication
BEBT-109Phase 2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
JS111Phase 2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
SutetinibPhase 2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ANS02Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BBT-207Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BH-30643Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BPI-361175Phase 1/2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
Dositinib MesylatePhase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
DZD6008Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
H002Phase 1/2Small moleculeEGFRWeak signalNo reviewed efficacy summary in this indication
JIN-A02Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
PH009-1Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
SilevertinibPhase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
STX-241Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
VRN110755Phase 1/2Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ALX2004Phase 1Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
AST2303Phase 1Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
EPI-326Phase 1Multispecific antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
HLX42Phase 1Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
HSK40118Phase 1Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 106 furthest-along competitors are listed; 505 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Erlotinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
2027 (4)
August 2027 (1)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2027-08 · NCT06483555 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04449874 · CT.gov ↗
What to watch
Phase 2Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma …Recruiting
Est. primary completion 2027-12-31 · NCT04981509 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 2Metastatic Colorectal Cancer, EGFR Amplified Colorectal CancerNot yet recruiting
Est. primary completion 2028-01-31 · NCT07941310 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head and Neck Cancer …Recruiting
Est. primary completion 2029-08-05 · NCT06997068 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 2Cirrhosis, Liver, Advanced Liver FibrosisNot yet recruiting
Est. primary completion 2030-06 · NCT04172779 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 1/2Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia CongenitaNot yet recruiting
Est. primary completion 2031-06-30 · NCT06545695 · CT.gov ↗
What to watch

See the full readout calendar ↗